Table 1.
Baseline characteristics of included RCTs
| Study | Year | Case (T/C, n) | Age (T/C, y) | Sex (male/female)
|
Intervention (T/C) | Duration | Stent (size/length, cm) | Outcome measured time | |
|---|---|---|---|---|---|---|---|---|---|
| T | C | ||||||||
| Deliveliotis et al11 | 2006 | 50/50 | 53.1/55.3 | 30/20 | 27/23 | 10 mg alfuzosin for 4 weeks/placebo | 4 weeks | 5F/26–28 | PI 4 weeks |
| Damiano et al12 | 2008 | 38/37 | – | 29/46 | 0.4 mg tamsulosin for 4 weeks/control | 2 weeks | 7F/− | PI and PR 1 week | |
| Beddingfield et al13 | 2009 | 26/29 | 45.8/44.0 | 7/19 | 16/13 | 10 mg alfuzosin for 8 days/placebo | 8.3/11.5 days | – | PI 3 days |
| Wang et al14 | 2009 | 79/75 | 50.1/51.5 | 63/16 | 58/17 | 0.4 mg tamsulosin for 2 weeks/placebo | 2 weeks | 7F/− | PI 1 week, and PR 2 weeks |
| Wang et al15 | 2009 | 75/71 | 50.4/50.8 | 61/14 | 55/16 | 0.4 mg tamsulosin for 2 weeks/placebo | 2 weeks | 7F/26 | PI 2 weeks |
| Navanimitkul and Lojanapiwat16 | 2010 | 21/21 | 46.1/51.5 | 9/12 | 6/15 | 0.4 mg tamsulosin for 4 weeks/control | 4 weeks | 6F/− | PI 2 weeks and 4 weeks |
| Shelbaia and Elnashar17 | 2011 | 69/67 | 35.0/29.0 | 44/25 | 50/17 | 0.4 mg tamsulosin for 4 weeks/control | 4 weeks | 6F/26 | – |
| Mokhtari et al18 | 2011 | 33/33 | – | – | – | 2 mg terazosin for 4 weeks/control | 4 weeks | 4.8F/− | PI 4 weeks |
| Kuyumcuoglu et al19 | 2012 | 21/21 | 45.2/42.9 | 15/6 | 7/14 | 4 mg doksazosin for 4 weeks/control | – | 4.7F/26–28 | PI 4 weeks |
| Nazim and Ather20 | 2012 | 65/65 | 37.8/40.1 | 52/13 | 49/16 | 10 mg alfuzosin for 1 week/placebo | >1 week | 4.7–6F/− | PI 1 week |
| Shalaby et al21 | 2013 | 82/81 | 41.3/44 | 55/27 | 50/31 | 0.4 mg tamsulosin for 2 weeks/control | – | – | PI 2 weeks |
| Tehranchi et al22 | 2013 | 23/24 | 38.4/33.4 | 16/7 | 21/3 | 2 mg terazosin for 13.5 days/placebo | 13.5/15.4 days | 4.8F/28 | PI 2 weeks |
| Singh et al23 | 2014 | 30/30 | 32.7/31.4 | 14/16 | 20/10 | 0.4 mg tamsulosin for 4 weeks/placebo | 6 weeks | 4–5F/24–26 | PI 4 weeks |
| Dellis et al24 | 2014 | 50/50 | 45.6/46.9 | 25/25 | 26/24 | 0.4 mg tamsulosin for 4 weeks/placebo | 4 weeks | 6F/24–26 | PI 1 and 4 weeks, and PR 4 weeks |
| Dellis et al24 | 2014 | 50/50 | 47.3/46.9 | 23/27 | 26/24 | 10 mg alfuzosin for 4 weeks/placebo | |||
| Park et al25 | 2015 | 20/23 | 54.5/48.7 | 9/11 | 14/9 | 0.2 mg tamsulosin for 2 weeks/control | 2 weeks | 6F/20–28 | PI 2 weeks, and PR 4 weeks |
| El-Nahas et al26 | 2015 | 40/40 | 41.4/40.8 | 19/21 | 24/16 | 0.4 mg tamsulosin for 5 weeks/placebo | 5.1/4.8 weeks | 6F/24–26 | PI 1–2 weeks |
Notes: Prulifloxacin 600 mg once daily for 5 days;12 ciprofloxacin 500 mg twice daily for 5 days;17 patients in α-blocker groups were administered an additional week of antibiotic therapy;19 ciprofloxacin 500 mg twice daily for 5 days;23 and 1 week of oral antibiotics (one tablet quinolone two times).25
Abbreviations: RCT, randomized controlled trial; T, treatment group; C, control group; y, years; PI, post-insertion of stent; PR, post-removal of stent.